DLBCL is the most commonly occurring form of non-Hodgkin lymphoma in the Western world, comprising one-third of all lymphomas in adults. Untreated DLBCL patients have an expected survival of <1 year, whereas with modern chemoimmunotherapy 75% of patients achieve complete remission and 64% of these individuals are alive, disease-free at 10 years, and cured.

READ FULL ARTICLE Curated publisher From Blood Journal